BECTON DICKINSON & CO (BDX) · Insider Trading (Form 4) SEC Filing

=== SEC Form 4 — Statement of Changes in Beneficial Ownership === Document Type: 4 Period of Report: 2026-06-01 10b5-1 Pre-arranged Plan: Yes --- Issuer --- Name: BECTON DICKINSON & CO (BDX) CIK: 0000010795 --- Reporting Owner --- Name: Polen Thomas E Jr CIK: 0001621793 Role: Director, Officer (Chairman, CEO and President) --- Non-Derivative Transactions --- [Transaction #1] Security: Common Stock Date: 2026-06-01 | Code: M (Exercise of derivative) Shares: +20,209 | Price: $126.16 Total Value: $2,549,567.44 Shares Owned After: 125,680 | Ownership: D (Direct) [Transaction #2] Security: Common Stock Date: 2026-06-01 | Code: D (Sale to issuer) Shares: -17,445 | Price: $146.15 Total Value: $2,549,586.75 Shares Owned After: 108,235 | Ownership: D (Direct) [Transaction #3] Security: Common Stock Date: 2026-06-01 | Code: S (Open market sale) Shares: -2,764 | Price: $146.35 Total Value: $404,511.40 Shares Owned After: 110,163 | Ownership: D (Direct) Footnotes: [F1] The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $145.21 through $147.49. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. [F2] Direct holdings reflect adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. to the number of shares underlying previously reported and unvested time-vested restricted stock units held by the reporting person. --- Derivative Transactions --- [Transaction #1] Security: Stock Appreciation Rights Date: 2026-06-01 | Code: M (Exercise of derivative) Shares: -20,209 | Price: $0.00 Exercisable: N/A | Expires: 2026-11-26 Shares Owned After: 0 | Ownership: D (Direct) Footnotes: [F3] Award terms reflect adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. [F3] Award terms reflect adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. [F4] The stock appreciation rights vested in four annual installments beginning November 26, 2017. --- Footnotes (Complete Index) --- F1: The reported sale price reflects the weighted average sale price for multiple transactions. The actual sales prices for the transactions ranged from $145.21 through $147.49. Full information regarding the number of shares purchased at each separate price will be provided to the Securities and Exchange Commission, the issuer or a security holder of the issuer upon request. F2: Direct holdings reflect adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. to the number of shares underlying previously reported and unvested time-vested restricted stock units held by the reporting person. F3: Award terms reflect adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. F4: The stock appreciation rights vested in four annual installments beginning November 26, 2017. --- Signature --- /s/ Donna Kalazdy, by power of attorney from Thomas E. Polen, Jr. (2026-06-03)